pgf2alpha

Dinoprost (Prostaglandin F2a) 是口服有效的、内源性的前列腺素 F 受体激动剂。它是在子宫内膜腔上皮和黄体中局部产生的溶酶激素。它在分娩过程中起关键作用。

Pgf2alpha 15-methyl ether主要用于预防产后出血。

Bimatoprost acid (17-phenyl trinor PGF2α) 是一种代谢稳定的 PGF2α 类似物，对 FP 受体具有潜在的拮抗活性。与 PGF2α 相比，它与绵羊黄体细胞上的 FP 受体结合的相对效力为 756%。

Carboprost (15(S)-15-Methyl Prostaglandin F2α) 是一种前列腺素 F2α 的代谢稳定的合成类似物。它能够刺激子宫收缩并引起流产，可用于子宫收缩乏力引起的产后出血，以及在妊娠中期终止妊娠。

Darbufelone (CI-1004) 是 PGF2α 和 LTB4 的非竞争性双重抑制剂。 Dabfilon 有效抑制 PGHS-2，对 PGHS-2 和 PGHS-1 的 Ki 为 10 μM，IC50 为 0.19 μM 和 20 μM。

Darbufelone mesylate (CI-1004 mesylate) 对细胞中 PGF2α 和 LTB4 产生有抑制作用。Darbufelone mesylate 对 PGHS-2 有抑制作用，IC50 值为 0.19 μM，对 PGHS-1 的IC50 值为 20 μM。

AL-3138 is a prostaglandin F2alpha (PGF2alpha) analogue which antagonizes FP prostanoid receptor-mediated inositol phosphates generation.

Bimatoprost isopropyl ester is an F-series prostaglandin analog, which has been approved as a hypotensive drug.

13,14-dihydro Prostaglandin F2α (13,14-dihydro PGF2α) is the analog of PGF2α which has no unsaturation in the lower side chain. It causes luteolysis in hamsters with a potency five times higher than PGF2α. The ED50 value for 13,14-dihydro PGF2α as a luteolytic agent in hamsters is 1.5 µg 100 g.[1]

15-keto Prostaglandin F2α 是 Prostaglandin F2α 的代谢物，可降低兔眼压。

Dinoprost tromethamine salt (PGF2α THAM) 是一种口服有效的前列腺素 F 受体激动剂。它是在子宫内膜腔上皮和黄体中局部产生的溶酶激素，在分娩过程中起关键作用。

Ebopiprant (OBE022) 是一个可口服且具有选择性和高效性的前列腺素 F2α (PGF2α) 受体拮抗剂，干扰 PGF0126α 与 FPR 的结合，可用于研究肥胖。

(+)-Cloprostenol is a analogue of prostaglandin F2α (PGF2α), and is selective prostaglandin receptor agonistic.

Tiaprost is a analog of prostaglandin F2α .

MBCQ 是选择性 cGMP 特异性磷酸二酯酶 (PDE V; PDE5) 抑制剂，IC50=19 nM。它通过特异性抑制 cGMP-PDE 来扩张冠状动脉。它对其他 PDE 同工酶没有抑制活性，IC50均大于 100 µM。

Cloprostenol sodium salt (ICI 80996 sodium salt) 是一种合成的前列腺素类似物，是 PGF2α受体的激动剂，具有黄体溶解性。

8,12-iso-iPF2α-VI, an isoprostane, arises from non-enzymatic, free radical-induced peroxidation of membrane lipids. It is the predominant isoprostane formed during lipid peroxidation and serves as a biomarker for oxidative stress. Detectable in hepatic tissue post CCl4-induced oxidative damage, 8,12-iso-iPF2α-VI levels are also elevated in the urine, blood, and cerebrospinal fluid of Alzheimer’s disease patients.

(15R)-Bimatoprost (15(R)-17-phenyl trinor PGF2α ethyl amide) 为一种前列腺素类似物，主要应用于青光眼及高眼压的治疗。该化合物为Bimatoprost的异构体，特征在于C-15位置的(β)羟基呈倒置构型。

Δ17-6-keto Prostaglandin F1α (Δ17-6-keto PGF1α), a cyclooxygenase (COX) metabolite produced from eicosapentaenoic acid (EPA) in a variety of tissues including seminal vesicles, lungs, polymorphonuclear leukocytes, and ocular tissues, alongside other 3-series COX products from EPA such as PGF3α, PGE3, and thromboxane B3, is potentially linked to a lower occurrence of glaucoma in individuals consuming a marine-rich (EPA-rich) diet.

Prostaglandin F2α serinol amide作为一种丝氨醇酰胺类G蛋白偶联受体，能够在人类非小细胞肺癌细胞中提高钙浓度。此外，Prostaglandin F2α在绵羊体内充当黄体溶解激素的角色，且可能作为脊髓伤害性介质存在。

1a,1b-Dihomo Prostaglandin F2α (1a,1b-dihomo PGF2α), a hypothetical product of adrenic acid in the COX pathway, is predominantly synthesized in the renal medulla, reflecting the selective distribution of adrenic acid in this region.

Prostaglandin F2α (PGF2α) 1,9-lactone, a lipid-soluble internal ester of PGF2α, demonstrates resistance to hydrolysis by human plasma esterases, maintaining its structure even after 20 hours of incubation under physiological conditions. Unlike PGF2α, this compound exhibits minimal antifertility and vasoactivity.

16,16-Dimethyl PGF2β, a metabolically stable analog of PGF2β, mitigates bronchospasm in asthma patients, albeit with lower potency compared to PGE2.

11β-13,14-Dihydro-15-keto PGF2α, a PGD2 metabolite in the 15-hydroxy PGDH pathway, is formed in human males upon infusion or inhalation of tritiated PGD2, with peak plasma levels of both 11β-PGF2α and 11β-13,14-dihydro-15-keto PGF2α observed within 10 minutes. In human lung homogenates, PGD2 is metabolized firstly to 11β-PGF2α and subsequently to 11β-15-keto-PGF2α in the presence of NAD+, but not to 11β-13,14-dihydro-15-keto PGF2α. Conversely, guinea pig liver and kidney homogenates can metabolize PGD2 to 11β-13,14-dihydro-15-keto PGF2α via 11β-PGF2α, with both NAD+ and NADP+ being requisite for this conversion.